Assessment of Iron Overload with T2 * Magnetic Resonance Imaging

Progress in Cardiovascular Diseases

Volumn 54, Issue 3, 2011, Pages 287-294

  Anderson, Lisa J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cardiac magnetic resonance T2 *; Iron chelation therapy; Iron overload cardiomyopathy; Thalassemia major

Indexed keywords

FERRITIN; IRON;

ARTICLE; ELECTRON SPIN RESONANCE; FERRITIN BLOOD LEVEL; HEART; HEART VENTRICLE FUNCTION; HUMAN; IMAGE ANALYSIS; IRON BLOOD LEVEL; IRON OVERLOAD; IRON STORAGE; LIVER; LIVER BIOPSY; LIVER FIBROSIS; LIVER LEVEL; MATHEMATICAL MODEL; NON TRANSFERRIN BOUND PLASMA IRON; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; QUANTITATIVE STUDY; REPRODUCIBILITY; SIGNAL DETECTION; TISSUE DISTRIBUTION; VALIDATION STUDY;

CARDIOMYOPATHIES; HUMANS; IRON; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; THALASSEMIA;

EID: 80054784168     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2011.07.004     Document Type: Article

References (59)

1. Modell B Khan M., Darlison M. Survival in beta thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000, 355:2051-2052.
2. Olivieri N.F., Nathan D.G., MacMillan J.H., et al. Survival in medically treated patients with homozygous beta-thalassaemia. N Engl J Med 1994, 331:574-578.
3. Marcus R.E., Davies S.C., Bantock H.M., et al. Desferrioxamine to improve cardiac function in iron-loaded patients with thalassaemia major. Lancet 1984, 1:392.
4. Henry W.L.N.A., Wiener M., Miller D.R., et al. Echocardiographic abnormalities in patients with transfusion-dependent anaemia and secondary myocardial iron deposition. Am J Med 1978, 64:547-555.
5. Nienhuis A.W., Griffith P., Strawczynski H., et al. Evaluation of cardiac function in patients with thalassaemia major. Ann N Y Acad Sci 1980, 344:384-396.
6. Ehlers K.H., Giardina P.J., Lesser M.E. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr 1991, 118:540-545.
7. Kremastinos D.T., Tiniakos G., Theodorakis G.N., et al. Myocarditis in beta-thalassaemia major. A cause of heart failure. Circulation 1995, 91:66-71.
8. Buja L.M., Roberts W.L. Iron in the heart. Etiology and clinical significance. Am J Med 1971, 51:209-221.
9. Link G., Pinson A., Hershko C. Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. Blood 1994, 83:2692-2697.
10. Link G., Pinson A., Hershko C. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J Lab Clin Med 1993, 121:127-134.
11. Link G., Tirosh R., Pinson A., et al. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med 1996, 127:272-278.
12. Hershko C., Link G., Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci 1998, 850:191-201.
13. Herschko C., Graham G., Bates C.W., et al. Non specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978, 40:255.
14. Link G., Pinson A., Hershko C. Heart cells in culture: a model of iron overload and chelation. J Lab Clin Med 1985, 106:147-153.
15. Parkes J.G., Hussain R.A., Olivieri N.F., et al. Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells. J Lab Clin Med 1993, 122:36-47.
16. Gutteridge J.M.C., Rowley D.A., Griffiths E., et al. Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci 1985, 68:463-467.
17. Porter J.B., Rafique R., Srichairatanakool S., et al. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use. Ann N Y Acad Sci 2005, 1054:155-168.
18. Olson L.J., Edwards W.D., McCall J.T., et al. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. JACC 1987, 10:1239-1243.
19. Olson L.J., Edwards W.D., Holmes D.R., et al. Endomyocardial biopsy in hemochromatosis: clinicopathological correlates in six cases. J Am Coll Cardiol 1989, 13:116-120.
20. Kirk P., Carpenter J.P., Tanner M.A., et al. Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2011, 13:8.
21. Brittenham G.M., Cohen A.R., McLaren C.E., et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993, 42:81-85.
22. Villeneuve J.P., Bilodeau M., Lepage R., et al. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol 1996, 25:172-177.
23. Emond M.J., Bronner M.P., Carlson T.H., et al. Quantitative study of the variability of hepatic iron concentrations. Clin Chem 1999, 45:340-346.
24. Doyle F.H., Pennock J.M., Banks L.M., et al. Nuclear magnetic resonance imaging of the liver: initial experience. AJR Am J Roentgenol 1982, 138:193-200.
25. Stark D.D., Moseley M.E., Bacon B.R., et al. Magnetic resonance imaging and spectroscopy of hepatic iron overload. Radiology 1985, 154:137-142.
26. Gomori J.M., Grossman R.I., Drott H.R. MR relaxation times and iron content of thalassemic spleens: an in vitro study. AJR Am J Roentgenol 1988, 150:567-569.
27. Kaltwasser J.P.G.R., Schalk K.P., et al. Non-invasive quantitation of liver iron-overload by magnetic resonance imaging. Br J Haematol 1990, 74:360-363.
28. Chezmar J.L., Nelson R.C., Malko J.A., et al. Hepatic iron overload; diagnosis and quantification by MR imaging. Gastrointest Radiol 1990, 15:27-31.
29. Jensen P.D., Jensen F.T., Christensen T., et al. Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. Br J Haematol 1994, 87:171-184.
30. Stark D.D. Hepatic iron overload: paramagnetic pathology. Radiology 1991, 179:333-335.
31. Gandon Y., Guyader D., Heautot J.F., et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology 1994, 193:533-538.
32. Hardy P.A., Henkelman R.M. Transverse relaxation rate enhancement caused by magnetic particulates. Magn Reson Imaging 1989, 7:265-275.
33. * (T2 star) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001, 22:2171-2179.
34. Brittenham G.M., Griffith P.M., Nienhuis A.W., et al. Efficacy of desferrioxamine in preventing complication of iron overload in patients with thalassaemia major. N Eng J Med 1994, 331:567.
35. Brittenham G.M., Farrell D.E., Harris J.W., et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982, 307:1671-1675.
36. Clark P.R., St Pierre T.G. Quantitative mapping of transverse relaxivity (1/T(2)) in hepatic iron overload: a single spin-echo imaging methodology. Magn Reson Imaging 2000, 18:431-438.
37. Anderson L.J., Wonke B., Prescott E., et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002, 360:516-520.
38. * validation and utility. Lancet 2003, 361:183.
39. * validation and utility. Lancet 2003, 361:182.
40. * validation and utility. Lancet 2003, 361:182-183.
41. Fitchett D.H., Coltart D.J., Littler W.A., et al. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res 1980, 14:719-724.
42. * mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005, 106:1460-1465.
43. *, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 2005, 112:535-543.
44. Ghugre N.R., Enriquez C.M., Gonzalez I., et al. MRI detects myocardial iron in the human heart. Magn Reson Med 2006, 56:681-686.
45. * magnetic resonance and cardiac iron. Circulation 2011, 123:1519-1528.
46. * cardiovascular magnetic resonance. Br J Haematol 2004, 127:348-355.
47. * magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009, 120:1961.
48. * cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008, 10:42.
49. *. Eur J Haematol 2006, 76:183-192.
50. * and field inhomogeneity maps in the human heart at 1.5T. Magn Reson Med 1998, 39:988-998.
51. * measurements in myocardial iron overload. J Magn Reson Imaging 2006, 23:9-16.
52. * measurements in iron-overloaded thalassemia: an in vivo study to investigate optimal methods of quantification. Magn Reson Med 2008, 60:1082-1089.
53. * cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003, 18:33-39.
54. * technique for myocardial iron measurement in thalassemia. J Magn Reson Imaging 2007, 25:1205-1209.
55. * technique for the quantification of tissue iron. Haematologica 2006, 91:1388-1391.
56. Brittenham G.M. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011, 364:146-156.
57. Papakonstantinou O., Alexopoulou E., Economopoulos N., et al. Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with beta-thalassemia major. J Magn Reson Imaging 2009, 29:853-859.
58. Wood J.C. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol 2007, 14:183-190.
59. * magnetic resonance in monitoring iron chelation therapy. Acta Haematol 2009, 122:146-154.